Mereo BioPharma Q1 net loss $6.7M; setrusumab Phase 3 fails primary endpoint, regulator engagement begun

Mereo BioPharma Group plc

2026-Q1 EPS reported -$0.01

Net loss of $6.7M in Q1 2026 vs $12.9M in Q1 2025; cash and equivalents $36.2M as of March 31, 2026.
Setrusumab Phase 3 studies in OI did not meet primary fracture-rate endpoints; high significance on BMD, vertebral fracture reduction, and PROs.
Mereo and partner Ultragenyx initiated regulatory discussions for pediatric OI path; no approved therapies exist.
Alvelestat partnership discussions active; single Phase 3 trial of ~220 patients with SGRQ (US) and lung density (EU) endpoints planned.

item 2.02 item 2.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Mereo BioPharma Group plc reported first quarter ended March 31, 2026 results: net income $6.7 million. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Net income: $6.7 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2026 was $6.7 million

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Mereo BioPharma Group plc filing history →

Source: SEC EDGAR

accession 0001193125-26-218290

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.